Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Everest Medicines Approved to Start China Phase IIb Trial of Lupus Therapy

publication date: Feb 27, 2024

Shanghai Everest Medicines and Kezar Life Sciences of South San Francisco will start a China Phase IIb trial of their partnered drug, zetomipzomib, in patients with lupus nephritis. Zetomipzomib is a novel first-in-class, selective immunoproteasome inhibitor with therapeutic potential for several autoimmune diseases. In 2023, Everest announced a $132 million deal ($7 million upfront) for China distribution rights to the candidate. At the time, Kezar said Everest, with its focus on renal and autoimmune diseases for Asian patients, was a good partner for zetomipzomib. More details....

Stock Symbols: (HK: 1952) (NSDQ: KZR)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital